NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.5181
-0.0219 (-4.06%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.5400
Open0.6200
Bid0.0000 x 1200
Ask0.0000 x 1300
Day's Range0.5000 - 0.6600
52 Week Range0.3700 - 5.0000
Volume14,483,305
Avg. Volume2,180,739
Market Cap32.512M
Beta (3Y Monthly)2.58
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • CNW Group4 days ago

    Neovasc Announces Resolution of Last Remaining Active Litigation

    VANCOUVER , April 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Company has resolved the three claims for correction of patent inventorship made by Edwards Lifesciences CardiAQ LLC ("CardiAQ") in the United States District Court for the District of Massachusetts ("the Court"). Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States , Canada and Europe .

  • PR Newswire5 days ago

    Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer™ Improves Diastolic Function in patients suffering from severe angina

    VANCOUVER, April 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the International Journal of Cardiology (the "IJC") has published a peer reviewed article demonstrating that coronary sinus ("CS") narrowing through the use of the Neovasc Reducer™ (the "Reducer") improves diastolic function and relaxation of the heart. "We are pleased to report evidence that CS narrowing may also improve diastolic function in patients with chronic refractory angina and proven myocardial ischemia.

  • PR Newswirelast month

    Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results

    NASDAQ, TSX: NVCN Recent Highlights The U.S. Food and Drug Administration (the "FDA") granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer") for the treatment ...

  • PR Newswirelast month

    Neovasc Wins German Court Appeal; Announces German Court's Decision to Dismiss CardiAQ's Claim to Co-inventorship of a European Patent for Tiara™

    VANCOUVER, March 21, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Higher Regional Court in Munich, Germany, on appeal by Neovasc, has dismissed the case in full, brought by Edwards Lifesciences CardiAQ LLC ("CardiAQ") against Neovasc in Germany. In this case, CardiAQ had originally claimed full ownership rights to one of Neovasc's European patent applications for its Tiara™ ("Tiara").

  • PR Newswirelast month

    Reducer Featured in Presentation at American College of Cardiology's Annual Meeting

    VANCOUVER, March 19, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that data on the Neovasc Reducer™ ("Reducer") was featured in session 725, titled, "Refractory Angina: Options for Patients With "No Options"" at the American College of Cardiology's ("ACC") 68th Annual Scientific Session and Expo ("ACC.19"). "We are pleased that today's ACC.19 session included an overview of our Reducer and its efficiency in narrowing the coronary sinus in refractory angina patients, which has resulted in an improvement in symptoms and quality of life for patients with refractory angina who were not candidates for revascularization.  A portion of the data discussed during the session was originally published in the New England Journal of Medicine in February 20151," stated Fred Colen, CEO of Neovasc.

  • PR Newswirelast month

    Neovasc Announces Closing of $5 Million Public Offering of Common Shares

    NASDAQ, TSX: NVCN VANCOUVER , March 15, 2019 /PRNewswire/ -   Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously ...

  • PR Newswirelast month

    Neovasc Completes Successful Quality System Surveillance Audit

    VANCOUVER, March 14, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it has successfully completed its 2019 mandatory Surveillance Audit with its Notified Body, resulting in the maintenance of the Regulatory Certification (EC marking) and maintenance of the ISO 13485: 2016 certification of the quality management system.

  • PR Newswirelast month

    Neovasc to Announce Year Ended December 31, 2018 Financial Results on Thursday, March 21

    Conference Call Scheduled for 4:30pm Eastern Time NASDAQ, TSX: NVCN VANCOUVER , March 13, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader ...

  • CNW Grouplast month

    Neovasc Announces Pricing of $5 Million Public Offering of Common Shares

    VANCOUVER , March 13, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today the pricing of its previously announced underwritten public offering (the "Offering") of 11,111,111 common shares of the Company (the "Common Shares") at a price to the public of US$0 .45 per Common Share, for aggregate gross proceeds to the Company of approximately US$5 million , before deducting the underwriting commission and estimated Offering expenses payable by the Company.  The Offering is expected to close on or about March 15, 2019 , subject to customary closing conditions. H.C. Wainwright & Co. (the "Underwriter") is acting as sole book-running manager for the Offering.

  • CNW Grouplast month

    Neovasc Announces Proposed Public Offering of Common Shares

    Neovasc Announces Proposed Public Offering of Common Shares

  • CNW Grouplast month

    Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares

    Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares

  • PR Newswire2 months ago

    Neovasc Announces Reducer™ Implant "Live Case" at the CRT Meeting in Washington, DC

    VANCOUVER, March 5, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that an implant procedure of the Neovasc Reducer™ ("Reducer") was featured in a "Live Case" broadcast at the Cardiovascular Research Technologies (CRT) meeting being held March 2-5, 2019 in Washington, DC. The implant procedure was performed by Dr. Francesco Giannini from the Maria Cecilia Hospital in Cotignola, Italy. Following the case there was a lot of interest from the CRT audience, including comments on the procedure and curiosity about the Reducer's mechanism of action.

  • PR Newswire2 months ago

    Neovasc's Tiara™ Mitral Valve Replacement Technology Featured in Update Presentation at the CRT 2019 Meeting

    VANCOUVER, March 4, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that its Tiara™ ("Tiara") transcatheter mitral valve replacement device was featured in an update presentation at the Cardiovascular Research Technologies (CRT) meeting being held March 2-5, 2019 in Washington, DC. The update presentation was provided by Danny Dvir, MD, of the Cardiac Clinic & Services at the University of Washington Medical Center, and titled, "TIARA: Design, Clinical Results and Next Steps" on Sunday, March 3rd.  The presentation provided an overview of the data from the 70 patients that have been treated to date with the Tiara mitral valve replacement device, including 25 patients in the TIARA-II European CE Mark Clinical Study, 23 patients in TIARA-I Early Feasibility Clinical Study and 22 patients in Special Access/Compassionate Use.